AMPLY Discovery
Revolutionizing drug discovery with AI-driven, nature-inspired solutions.. [Contact for Pricing]
Last verified:
What is AMPLY Discovery?
AMPLY Discovery is a UK-based biotech company that transforms drug discovery by combining artificial intelligence with evolutionary biology to identify novel therapeutic molecules from the 'dark genome'—the 98% of the genome largely ignored by traditional drug developers. The company's AMPLYfolio AI platform digitizes life's diversity using next-generation sequencing, creating a virtual library of billions of potential drug candidates that are then bio-printed into tangible molecules for real-world testing in hospital labs.
The platform specializes in tackling complex diseases including aggressive cancers (Acute Myeloid Leukaemia, Triple Negative Breast Cancer) and drug-resistant infections (Multi-drug Resistant Tuberculosis, Cystic Fibrosis-associated lung infections). It uses machine learning to mine metagenomic, metatranscriptomic, and genomic data to discover novel antimicrobial peptides (AMPs) and RNAi therapeutics that traditional tools miss, offering rapid kill times against drug-resistant ESKAPE pathogens and personalized treatment options based on genetic makeup.
AMPLY Discovery operates as a drug discovery studio that develops and validates novel drug candidates, then out-licenses them to larger biopharma partners. The company focuses on genetically-mediated cancers in a $157 billion market and is positioning itself for the emerging antibiotic resistance market projected to become a trillion-dollar problem by 2050. Their discoveries have been trialed in top hospital labs against real diseases.
The tool is designed for biopharma companies, pharmaceutical researchers, biotech startups, and academic institutions working in drug discovery. It serves both human and animal health sectors, with particular emphasis on managing topical skin and tissue infections. The platform democratizes drug discovery by making it accessible beyond big biopharma, using 'serendipity at scale' to accelerate the discovery of new drug candidates.
AMPLY Discovery pricing
Pricing model: Freemium
AMPLY Discovery does not offer a publicly advertised free tier or standard SaaS subscription model. As a biotech startup, the pricing model is likely enterprise/partner licensing or internal R&D pipeline development. The company operates on a B2B model, partnering with pharmaceutical companies to bring drug discoveries to market and out-licensing novel candidates to larger biopharma partners. Access is typically through bespoke partnerships or collaboration in pharmaceutical/biotech contexts rather than direct commercial purchase. The company has secured €1.6 million from Innovate UK under the Microbial Accelerator Programme and received strategic investment from Keeps Biomed (subsidiary of South Korean Keeps Biopharma), indicating their business model focuses on pipeline development and partnerships rather than end-user software sales.
AMPLY Discovery pros
- Accelerates drug discovery timeline significantly compared to traditional methods
- Accesses the 98% dark genome ignored by conventional drug developers
- Identifies molecular targets traditional tools miss using custom ML algorithms
- Unified digital-to-physical loop from sequencing to lab validation
- Rapid kill times as low as 40 minutes against drug-resistant ESKAPE pathogens
- Molecules soluble in low-cost formulations for over 30 days
- Highly stable and recoverable when nebulised for inhalation therapies
- Multiple modes of bacterial killing action prevent resistance development
- Capable of complex biofilm disruption for difficult infections
- Active against complex isolates with multiple pathogens present simultaneously
- RNAi therapeutics specifically target and silence cancer-related genes
- Fewer side effects compared to traditional chemotherapy treatments
- Can be designed to target almost any gene for personalized medicine
- Effective for targeting genes involved in chemotherapy resistance
- Automates data ingestion of large-scale biological sources including genomics and metagenomics
- Bio-printing enables rapid synthesis and validation of discovered molecules
- Proven track record with discoveries trialed in top hospital labs
AMPLY Discovery cons
- No publicly advertised free tier or trial access for individual users
- Access requires partnership or collaboration rather than simple sign-up
- Pricing model not publicly detailed—likely enterprise licensing only
- Requires technical expertise in genomics and bioinformatics to maximize capabilities
- Limited public user reviews and feedback as a newer company
- Integration with existing pharmaceutical systems may present challenges
- Effectiveness heavily dependent on quality of input biological data
- Steep initial learning curve for power features like custom ontologies
Frequently asked questions about AMPLY Discovery
What is AMPLY Discovery?
AMPLY Discovery is a UK-based biotech company that turns the 98% of the genome largely ignored by drug developers (the 'dark genome') into a pipeline of first-in-class therapeutics. The company combines AI, next-generation sequencing, and synthetic biology to mine natural biological diversity for novel therapeutic molecules, using their AMPLYfolio AI platform to process genomic, transcriptomic, and metagenomic data.
How does AMPLY Discovery's AI platform work?
The AMPLYfolio AI platform digitizes life's diversity using next-generation sequencing, creating a billion potential solutions on a billion virtual petri dishes. It uses custom machine learning algorithms and metadata tagging to identify regions of interest in biological datasets that traditional tools miss. These digital findings are then bio-printed into tangible molecules (peptides, proteins, RNAi) for real-world testing and validation in hospital labs.
What diseases does AMPLY Discovery focus on?
AMPLY Discovery is currently working on four key disease programs: Acute Myeloid Leukaemia (AML), Triple Negative Breast Cancer (TNBC), Multi-drug Resistant Tuberculosis (MDRTB), and Cystic Fibrosis-associated acute lung infections. The company focuses on genetically-mediated cancers and novel antimicrobials for drug-resistant infections.
What are AMPs and how do they work?
AMPs (Antimicrobial Peptides) discovered by AMPLY have rapid kill times as low as 40 minutes against key drug-resistant ESKAPE pathogens. They are soluble in low-cost formulations for over 30 days, stable and highly recoverable when nebulised, have various modes of bacterial killing action, can disrupt complex biofilms, and remain active against complex isolates with multiple pathogens present.
What is RNAi therapy and how does AMPLY use it?
RNAi (RNA interference) therapeutics from AMPLY specifically target and silence cancer-related genes with fewer side effects compared to traditional therapies. They can be designed to target almost any gene, used alongside other treatments to enhance effectiveness, target genes involved in chemotherapy resistance, and allow for personalized treatment based on the genetic makeup of an individual's tumor.
How much does AMPLY Discovery cost?
AMPLY Discovery does not have publicly advertised pricing. As a biotech startup, the model is likely enterprise/partner licensing or internal R&D pipeline development rather than a typical SaaS subscription. There is no free tier advertised, and access is typically through bespoke partnerships or collaboration in pharmaceutical/biotech contexts. Interested parties should contact the company directly through their website for partnership discussions.
Who is AMPLY Discovery for?
AMPLY Discovery serves biopharma companies, pharmaceutical researchers, biotech startups, and academic institutions working in drug discovery. The platform is designed for organizations tackling complex diseases like aggressive cancers and antimicrobial-resistant infections. It operates on a B2B model, partnering with larger pharmaceutical companies to bring drug discoveries to market, making it suitable for both human and animal health sectors.
Has AMPLY Discovery's discoveries been tested?
Yes, AMPLY Discovery's discoveries have been trialed in top hospital labs and pitted against real diseases. The company develops and validates novel drug candidates before out-licensing them to larger biopharma partners. Their platform has progressed compounds through pre-clinical pipelines with the company securing significant funding including €1.6 million from Innovate UK.
How do I access or partner with AMPLY Discovery?
Access to AMPLY Discovery is typically through collaboration or partnership rather than simple sign-up. Since it is a research/biotech-oriented platform, interested parties should visit their website at amplydiscovery.com and contact the company for a demo or partnership discussion. The company is focused on becoming a great drug discovery studio and seeks partnerships with larger biopharma companies for out-licensing opportunities.
What makes AMPLY Discovery unique compared to other drug discovery companies?
AMPLY Discovery uniquely leverages 'serendipity at scale' by combining AI with evolutionary biology to access the dark genome (98% of the genome ignored by developers). Their unified digital-to-physical loop automates data ingestion, AI scanning for molecular targets, bio-printing of molecules, and experimental validation. They can find and synthesize compounds that other tools miss, discrimination through custom ML and metadata tagging, and have secured recognition as one of the 100 hottest Irish start-ups to watch in 2025.